about
Carcinogenesis and cancer prevention: the process and the disease deserve a better understandingThe restrained expression of NF-kB in renal tissue ameliorates folic acid induced acute kidney injury in miceThe ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytesThe DACH/EYA/SIX gene network and its role in tumor initiation and progressionmRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 InteractionLoss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices.Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse alleleActivities of Z-ajoene against tumour and viral spreading in vitro.Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.Resveratrol induces p53-independent, X-linked inhibitor of apoptosis protein (XIAP)-mediated Bax protein oligomerization on mitochondria to initiate cytochrome c release and caspase activation.The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 InhibitorNatural compounds with proteasome inhibitory activity for cancer prevention and treatment.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.NOXA as critical mediator for drug combinations in polychemotherapy.CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.Apoptosis pathways as promising targets for skin cancer therapy.Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 proteinGain-of-function miRNA signature by mutant p53 associates with poor cancer outcomep53 regulates the transcription of the anti-inflammatory molecule developmental endothelial locus-1 (Del-1)Induction of lung cancer cell apoptosis through a p53 pathway by [6]-shogaol and its cysteine-conjugated metabolite M2.Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.Inhibitors of MDM2 and MDMX: a structural perspective.From protein interaction networks to novel therapeutic strategies.Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.Polypharmacology of small molecules targeting the ubiquitin-proteasome and ubiquitin-like systems.Cytotoxic effect of p-Coumaric acid on neuroblastoma, N2a cell via generation of reactive oxygen species leading to dysfunction of mitochondria inducing apoptosis and autophagy.Lack of p53 induction in fish cells by model chemotherapeutics.Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells.Effect of distinct anticancer drugs on the phosphorylation of p53 protein at serine 46 in human MCF-7 breast cancer cells.Impact of the p53 status of tumor cells on extrinsic and intrinsic apoptosis signaling.Induction of antiproliferative effect by diosgenin through activation of p53, release of apoptosis-inducing factor (AIF) and modulation of caspase-3 activity in different human cancer cells.Oncogenes do not Fully Override Cell-intrinsic Traits: Pronounced Impact of the Cellular Programme.ATP stimulates MDM2-mediated inhibition of the DNA-binding function of E2F1.A quantitative model of cellular senescence influence on cancer and longevity.Checkpoint genes, ageing, and the development of cancer.ZGDHu-1 for cancer therapy.Modulatory role of betulinic acid in N-nitrosodimethylamine-induced hepatorenal toxicity in male Wistar rats.p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid.E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
P2860
Q24801003-041B965A-9B41-4492-B879-DC0A4C83E1F4Q27318623-3D015BE7-AF71-4DF5-A9C0-1D8E8B924311Q28241779-363E4B66-282A-410E-AEED-ED52F3A8429FQ28263832-35C939B4-B866-4683-9F65-A54970E34695Q28386936-C9352B78-0B7E-40AC-98DD-277B295982BDQ30480500-D12CEBE2-0834-41B7-80C1-7E7A96B1EC5EQ34273969-887737CE-2364-492F-A983-064B335A67CEQ34631061-8CC1DA02-25EC-4676-A737-1711B4DC1568Q35058579-F7EC40A8-03AA-4899-BDF6-04B2848E3785Q35309349-17139AAB-8BF7-41A6-99B8-6C53158F1A48Q35692130-659798A9-FABA-4C6D-8ED0-D055D405A0D7Q35828472-31B39A36-086A-49DA-8D71-8E724D58791FQ35836881-FB1AF316-E4B7-4336-BF4E-9F1E9759A756Q36071973-98680675-FE3E-403A-88D6-9CD73664744EQ36173604-7E5ACA52-6F39-40B6-BBC1-E8DF745EBF2CQ36815310-ADDE19FB-51A3-423B-B823-61D036DEC9B4Q36962430-720797DB-8D27-443C-AEAE-6DCD7F6DF9FCQ36998156-A964AA86-1857-4F78-A82C-5203AF46D9D1Q37420171-5014B271-47E1-43F7-B2F5-A15454BEE035Q37697336-9AD65EB0-D224-4CBB-BCD2-23C8C28F1A52Q37726102-81750D35-F0F3-48AA-A597-FEEB18F678D7Q37855826-385EA94E-3EE7-4495-8D44-2D4B30E95A6FQ38008992-3C5E17F0-85FB-4D5C-BD0C-162BEF9C2359Q38258843-9CC1449A-139C-4F43-BE42-CA82DE243F0BQ38492748-41F00224-2683-43C5-926F-2E749B6B80C1Q39001612-6A9ABBE0-6549-4F63-BCC4-1D26CEBBB437Q39386130-77F4D5CC-09AB-4AA0-B5A7-6D9218449FB9Q40105893-989A1ED1-70FB-4A49-A0C7-EDF5B9061E4CQ40150740-779546E8-2E66-4C66-9CA5-2919169E460BQ40311218-76606029-5116-4B86-998D-72AE8E7FF7C0Q40540682-FF8EDC7E-D9B9-413B-81F4-6C50A00709D8Q42575797-265A41F6-2605-4A7A-9BD8-B37BF6109E18Q43675801-98518F01-0438-4CDF-8EF8-F356E268001DQ44877386-61B553D8-21E1-4222-B93D-BBE005742E4EQ46100284-A9DC8647-53B3-4BCB-AF9F-A29983B0FEEAQ49436424-528BF90B-1D4D-4E5B-9555-AAF7071FACA3Q50260935-723C916F-485F-464E-8118-53DC6CD34653Q51035665-6BD55331-892E-4C18-978F-BCEAEFB235B4Q53168345-62D9902A-A7FA-4A5F-A4EC-698149B66244
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
P53: an ubiquitous target of anticancer drugs.
@ast
P53: an ubiquitous target of anticancer drugs.
@en
P53: an ubiquitous target of anticancer drugs.
@nl
type
label
P53: an ubiquitous target of anticancer drugs.
@ast
P53: an ubiquitous target of anticancer drugs.
@en
P53: an ubiquitous target of anticancer drugs.
@nl
prefLabel
P53: an ubiquitous target of anticancer drugs.
@ast
P53: an ubiquitous target of anticancer drugs.
@en
P53: an ubiquitous target of anticancer drugs.
@nl
P2860
P356
P1476
P53: an ubiquitous target of anticancer drugs.
@en
P2860
P304
P356
10.1002/IJC.10158
P577
2002-03-01T00:00:00Z